Cobolimab Plus Dostarlimab Achieves Clinical Responses in Advanced Melanoma

Source: Onc Live, June 2022

Treatment with the combination of cobolimab and dostarlimab (Jemperli) led to an overall objective response rate (ORR) and immune-related ORR of 42.9% (n = 12/28) consisting of all partial responses (PRs) in patients with advanced or metastatic melanoma, according to data from the phase 1 AMBER study (NCT02817633) presented at the 2022 ASCO Annual Meeting.

“Cobolimab plus dostarlimab showed preliminary antitumor activity, supporting the rationale for dual TIM-3 and PD-1 blockade in advanced or metastatic solid tumors,” lead study author Antoni Ribas, MD, PhD, of the University of California, Los Angeles, said in a presentation of the data.

TIM-3 is an immune checkpoint receptor that is associated with inhibitory antitumor responses, but concurrent TIM-3 and PD-1 blockade is more effective at reducing tumor growth than either pathway alone. Cobolimab is a selective anti–TIM-3 monoclonal antibody that activates immune cell function and induces substantial antitumor activity in combination with anti–PD-1 agents like dostarlimab.